Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation | Zendy

Donald D. Anthony | Zendy; Mark Sulkowski | Zendy; Laura Smeaton | Zendy; Sofi Damjanovska | Zendy; Carey L. Shive | Zendy; Corinne Kowal | Zendy; Daniel E. Cohen | Zendy; Debika Bhattacharya | Zendy; Beverly AlstonSmith | Zendy; Ashwin Balagopal | Zendy; David Wyles | Zendy

Open Access

Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation

Author(s) -

Donald D. Anthony,

Mark Sulkowski,

Laura Smeaton,

Sofi Damjanovska,

Carey L. Shive,

Corinne Kowal,

Daniel E. Cohen,

Debika Bhattacharya,

Beverly AlstonSmith,

Ashwin Balagopal,

David Wyles

Publication year - 2020

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jiaa254

Subject(s) - ombitasvir , paritaprevir , dasabuvir , coinfection , ritonavir , hepatitis c virus , medicine , hepatitis c , virology , immunology , viral load , ribavirin , virus , antiretroviral therapy

Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research